Scientists test arthritis drug in bold bid to shrink hidden HIV
NCT ID NCT07028385
Summary
This study is testing if a drug called baricitinib, used for rheumatoid arthritis, is safe and can reduce the hidden, inactive HIV that persists in the body even with effective treatment. It involves 30 adults with well-controlled HIV who will take either the drug or a placebo pill daily for 12 weeks. The main goal is to check for safety and see if the drug affects certain immune system signals and the size of the hidden HIV reservoir.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fundació Lluita contra les Infeccions - Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, 08916, Spain
Conditions
Explore the condition pages connected to this study.